Synchron Stentrode

The Synchron Stentrode is an endovascular brain-computer interface implant that does not require open-brain surgery. Implanted via the jugular vein, it detects brain signals to enable patients with severe paralysis (ALS) to communicate via thought. The Stentrode has been tested in COMMAND (US) and SWITCH (Australia) clinical trials with no serious device-related adverse events.

Yes. Synchron Stentrode is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.

Synchron Stentrode is made by Synchron, based in New York, NY, USA, founded in 2016.

5 verified deployments of Synchron Stentrode are on the DEPLOY registry, including at Pittsburgh, Pennsylvania, USA, Buffalo, New York, USA, New York, New York, USA.

Synchron Stentrode is in pilot deployments with named customers and is not yet broadly for sale.

On the DEPLOY registry, comparable wearable robots to Synchron Stentrode include Bee AI Wearable, Bee Pioneer, Esper Hand, Mentra Live.

Synchron Stentrode and Bee AI Wearable (Bee · 4 deployments) are both wearable robots on the DEPLOY registry. Synchron Stentrode has 5 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.

On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Synchron Stentrode ranks in roughly the top 5% of wearable models tracked by the registry.

Synchron Stentrode is at the pilot stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Pilot stage means at least one named-customer trial deployment is verified.

Synchron Stentrode has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.